Progenics Pharmaceuticals
Progenics Pharmaceuticals is a biopharmaceutical company based in Tarrytown, New York, focused on developing and commercializing innovative therapeutics for cancer and related conditions. The company's product pipeline includes several candidates such as Azedra, a radiotherapeutic for treating pheochromocytoma and paraganglioma; PyL and 1404, imaging agents for prostate cancer; and 1095, a treatment for metastatic castration-resistant prostate cancer currently in Phase II clinical trials. Additionally, Progenics is advancing PSMA ADC, a human monoclonal antibody-drug conjugate also in Phase II testing. The company offers Relistor, a first-in-class treatment for opioid-induced constipation, which is licensed for worldwide distribution, excluding Japan. Progenics also utilizes artificial intelligence technologies to enhance imaging analysis for prostate cancer diagnostics. Founded in 1986, Progenics collaborates with various partners, including Salix Pharmaceuticals for Relistor and Amgen for antibody development, reinforcing its commitment to advancing cancer care through targeted therapies and innovative technologies.
Exini Diagnostics
Acquisition in 2015
EXINI Diagnostics AB is a Swedish company specializing in medical decision support solutions for hospitals globally. Founded in 1999 and based in Lund, the company develops advanced software for the automated analysis of diagnostic images, focusing on areas such as prostate cancer, cardiac health, and dementia. Its key products include EXINI bone, which aids in diagnosing prostate cancer and analyzing bone scintigraphy; EXINI heart, for assessing myocardial perfusion; and EXINI brain, designed to diagnose dementia through cerebral blood flow scans. Utilizing unique image analysis technologies and artificial intelligence, EXINI Diagnostics aims to enhance the accuracy and efficiency of medical diagnoses, ultimately supporting healthcare practitioners in managing patient care. The company operates as a subsidiary of Progenics Pharmaceuticals.
Molecular Insight Pharmaceuticals
Acquisition in 2013
Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet medical needs. They are focused on discovering, developing and commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.